General Information of Drug (ID: DM906JK)

Drug Name
Pyrrolidine-1-carbonitrile Drug Info
Synonyms
Pyrrolidine-1-carbonitrile; 1530-88-7; 1-Pyrrolidinecarbonitrile; 1-Cyanopyrrolidine; N-Cyanopyrrolidine; CHEMBL262697; QJRYYOWARFCJQZ-UHFFFAOYSA-N; pyrrolidinecarbonitrile; cyanopyrrolidine; Cyano-Pyrrolidine; NSC44225; EINECS 216-234-3; Tetramethylenecyanamide; AC1L2KEM; AC1Q4SLA; 1-pyrrolidine carbonitrile; CTK0I1775; DTXSID90165192; MolPort-000-145-877; ZINC1676633; KS-00002AX2; NSC-44225; 4756AD; BDBM50095495; SBB059310; AKOS006227753; MCULE-2010942719; PS-9344; CJ-27397; AN-49391; KB-65041; FT-0607667; ST51044369; P2337; A827637
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
73737
CAS Number
CAS 1530-88-7
TTD Drug ID
DM906JK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Cathepsin K (CTSK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Odanacatib DM1EO3G Osteoporosis FB83.0 Phase 3 [2]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [3]
VEL-0230 DMDSC63 Rheumatoid arthritis FA20 Phase 1 [4]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [5]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [5]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [5]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [6]
PMID27998201-Compound-15 DMOB8LU Pain MG30-MG3Z Patented [5]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R Pain MG30-MG3Z Patented [5]
PMID27998201-Compound-8 DMZK0SY N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [1]

References

1 Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43.
2 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
3 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
4 Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
5 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
6 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.